Investigate the Effect of AZD1656 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Type 2 Diabetes Mellitus (T2DM) Patients
Primary Purpose
Type 2 Diabetes Mellitus
Status
Completed
Phase
Phase 1
Locations
United Kingdom
Study Type
Interventional
Intervention
Warfarin
Placebo
AZD1656
Sponsored by

About this trial
This is an interventional treatment trial for Type 2 Diabetes Mellitus focused on measuring Diabetes, Type 2, Warfarin, drug-drug interaction
Eligibility Criteria
Inclusion Criteria:
- Clinical diagnosis of T2DM treated with at least 1000 mg metformin as a single treatment or in combination with one other oral anti-diabetics for at least 2 months prior to screening. Doses of anti-diabetic treatment stable for at least 1 month
- Fasting plasma glucose (FPG) at screening in the range of 6.0 to 15.0 mmol/L (108 to 270 mg/dL) and FPG in the range of 7.5 to 13.0 mmol/L (135 to 234 mg/dL) on Day 1
- Haemoglobin (Hb) A1c >6.5% at screening
Exclusion Criteria:
- Use of drugs with anticoagulant effects 3 weeks prior to first warfarin dosing
- Use of amiodarone within 3 months prior to screening and the use of potent CYP450 inhibitors
- Previous treatment with warfarin on clinical indication
Sites / Locations
- Research Site
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
1
2
Arm Description
twice daily on Day 1 to Day 10, with Warfarin on Day 4
twice daily on Day 1 to Day 10, with Warfarin on Day 4
Outcomes
Primary Outcome Measures
To evaluate the pharmacokinetics of warfarin after a single dose when administered alone and in combination with AZD1656 at steady state by assessment of AUC and Cmax of both enantiomers of warfarin (S- and R-warfarin).
Secondary Outcome Measures
To evaluate the anticoagulant activity of warfarin upon co-administration with AZD1656 by assessment of prothrombin time (PT) and international normalised ratio (INR).
To evaluate the safety of AZD1656 in combination with warfarin by assessment of electrocardiogram, weight, pulse, blood pressure, laboratory variables (including 7-point glucose), physical examination and adverse events
To describe the pharmacokinetics of AZD1656 and its metabolite during concomitant warfarin administration by assessment of AUC0-24, Cmax, Ctrough, tmax, t1/2 and CL/F (AZD1656 only).
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01103609
Brief Title
Investigate the Effect of AZD1656 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Type 2 Diabetes Mellitus (T2DM) Patients
Official Title
An Open-Label, Randomised, Placebo-Controlled, Two-Way Crossover, Phase I Single Centre Study in Type 2 Diabetes Mellitus Patients Treated With Metformin to Evaluate the Pharmacokinetics and Pharmacodynamics of Warfarin During Co-administration With AZD1656
Study Type
Interventional
2. Study Status
Record Verification Date
November 2010
Overall Recruitment Status
Completed
Study Start Date
April 2010 (undefined)
Primary Completion Date
August 2010 (Actual)
Study Completion Date
August 2010 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
AstraZeneca
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study is to determine whether AZD1656 will affect the Pharmacokinetics and Pharmacodynamics of Warfarin in T2DM patients.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type 2 Diabetes Mellitus
Keywords
Diabetes, Type 2, Warfarin, drug-drug interaction
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Crossover Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
16 (Actual)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
twice daily on Day 1 to Day 10, with Warfarin on Day 4
Arm Title
2
Arm Type
Placebo Comparator
Arm Description
twice daily on Day 1 to Day 10, with Warfarin on Day 4
Intervention Type
Drug
Intervention Name(s)
Warfarin
Intervention Description
Oral tablet od on Day 4
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Oral tablet bd, stepwise increased
Intervention Type
Drug
Intervention Name(s)
AZD1656
Intervention Description
Oral tablet bd, stepwise increased
Primary Outcome Measure Information:
Title
To evaluate the pharmacokinetics of warfarin after a single dose when administered alone and in combination with AZD1656 at steady state by assessment of AUC and Cmax of both enantiomers of warfarin (S- and R-warfarin).
Time Frame
Serial PK blood samples will be taken on days 4-10 during the treatment periods
Secondary Outcome Measure Information:
Title
To evaluate the anticoagulant activity of warfarin upon co-administration with AZD1656 by assessment of prothrombin time (PT) and international normalised ratio (INR).
Time Frame
Serial blood samples for warfarin PD measurements will be taken on days 4-10 during the treatment periods
Title
To evaluate the safety of AZD1656 in combination with warfarin by assessment of electrocardiogram, weight, pulse, blood pressure, laboratory variables (including 7-point glucose), physical examination and adverse events
Time Frame
Safety assessments will be monitored throughout the study, from screening visit until follow up visit.
Title
To describe the pharmacokinetics of AZD1656 and its metabolite during concomitant warfarin administration by assessment of AUC0-24, Cmax, Ctrough, tmax, t1/2 and CL/F (AZD1656 only).
Time Frame
Serial PK blood samples will be taken on days 4-10 during the treatment periods
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Clinical diagnosis of T2DM treated with at least 1000 mg metformin as a single treatment or in combination with one other oral anti-diabetics for at least 2 months prior to screening. Doses of anti-diabetic treatment stable for at least 1 month
Fasting plasma glucose (FPG) at screening in the range of 6.0 to 15.0 mmol/L (108 to 270 mg/dL) and FPG in the range of 7.5 to 13.0 mmol/L (135 to 234 mg/dL) on Day 1
Haemoglobin (Hb) A1c >6.5% at screening
Exclusion Criteria:
Use of drugs with anticoagulant effects 3 weeks prior to first warfarin dosing
Use of amiodarone within 3 months prior to screening and the use of potent CYP450 inhibitors
Previous treatment with warfarin on clinical indication
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Stanko Skrtic
Organizational Affiliation
AstraZeneca
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
James Ritter, Prof
Organizational Affiliation
Quintiles Drug Research Unit
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Mirjana Kujacic
Organizational Affiliation
AstraZeneca
Official's Role
Study Chair
Facility Information:
Facility Name
Research Site
City
London
Country
United Kingdom
12. IPD Sharing Statement
Learn more about this trial
Investigate the Effect of AZD1656 on the Pharmacokinetics and Pharmacodynamics of Warfarin in Type 2 Diabetes Mellitus (T2DM) Patients
We'll reach out to this number within 24 hrs